



July 31, 2018

To Whom It May Concern:

Company Name: KIRIN HOLDINGS COMPANY, LIMITED
Name and Title of Representative: Yoshinori Isozaki, President & CEO
Code Number: 2503
Head Office:
4-10-2, Nakano, Nakano-ku, Tokyo 164-0001, Japan
Name and Title of Contact Person:
Tetsuya Fujiwara
Director of Group Corporate Communications
Telephone Number: (03) 6837-7015

Notice Regarding Change of Subsidiary's Trade Name

Kyowa Hakko Kirin Co., Ltd. (President and COO: Masashi Miyamoto, hereinafter, "Kyowa Hakko Kirin"), a subsidiary of Kirin Holdings Company, Limited and a key Group company in charge of Pharmaceuticals and Bio-chemicals Businesses in the Kirin Group, has announced that, at a meeting held on July 31, 2018, the Board of Directors resolved to submit a proposal at the 96th Ordinary General Meeting of Shareholders, to be held in March 2019, to change its trade name and partially amend its Articles of Incorporation.

1. Change of subsidiary's trade name

(1) Reason for change

Kyowa Hakko Kirin has been steadily deploying initiatives aimed at evolving into a global specialty pharmaceutical company, and as global strategic products are steadily being developed and brought to market, it has been accelerating the business overseas.

Most of the Kyowa Hakko Kirin Group's pharmaceutical group companies in the U.S. and Europe have already changed their names to Kyowa Kirin, and Kyowa Hakko Kirin believes changing its trade name will cultivate a greater sense of unity among the Group's operation, promote the Kyowa Kirin brand on a worldwide basis and accelerate its realization as a global specialty pharmaceutical company.

(2) New trade name

KYOWA KIRIN KABUSHIKI KAISHA ("Kyowa Kirin Co., Ltd." in English)

(3) Date of change

July 1, 2019

Kyowa Hakko Kirin plans for the Kyowa Hakko Kirin Group's overseas pharmaceutical group companies currently using the "Kyowa Hakko Kirin" name, which are mostly located in Asia, to also change their names to Kyowa Kirin as soon as the necessary preparations are in place.

2. Partial amendments to the Articles of Incorporation of the subsidiary

(1) Reason for amendments

As stated in "1. Change of subsidiary's trade name, (1) Reason for change," Kyowa Hakko Kirin plans to amend Article 1 of its current Articles of Incorporation. The effective date of this amendment to the Articles of Incorporation will be July 1, 2019.

(2) Details of amendments

The following table shows the current Articles of Incorporation and proposed Articles of Incorporation after amendments. Underlined parts are planned to be amended.

Current Articles of Incorporation	Proposed Articles of Incorporation after amendments
Article 1. (Trade name) The Company shall be called <u>KYOWA HAKKO KIRIN KABUSHIKI KAISHA</u> , which shall be expressed in English as <u>Kyowa Hakko Kirin Co., Ltd.</u>	Article 1. (Trade name) The Company shall be called <u>KYOWA KIRIN KABUSHIKI KAISHA</u> , which shall be expressed in English as <u>Kyowa Kirin Co., Ltd.</u>

3. Overview of the subsidiary

(1) Company name	Kyowa Hakko Kirin Co., Ltd.
(2) Location	1-6-1 Otemachi, Chiyoda-ku, Tokyo
(3) Name and title of the representative	President and COO Masashi Miyamoto
(4) Business activities	Manufacturing and sales of ethical pharmaceuticals, and as the holding company in the Kyowa Hakko Kirin Group, overseeing operations of group companies engaged in biochemical business.
(5) Capital	26,745 million yen (as of December 31, 2017)

END